Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1292-1300

  Reka, Ajaya Kumar ^a   Chen, Guoan ^a,b   Jones, Richard C ^c   Amunugama, Ravi ^c   Kim, Sinae ^d   Karnovsky, Alla ^a   Standiford, Theodore J ^a   Beer, David G ^a,b   Omenn, Gilbert S ^a,d   Keshamouni, Venkateshwar G ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MS BIOWORKS   (United States)

^d RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

A549 CELL LINE; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION ASSOCIATED SECRETORY PHENOTYPE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; MALE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL ANALYSIS; TANDEM MASS SPECTROMETRY; UPREGULATION; ADULT; AGED; BIOLOGY; CANCER GRADING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROTEOMICS; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTEOMICS;

EID: 84905383275     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu041     Document Type: Article

References (50)

1. Detterbeck, F.C. et al. (2009) The new lung cancer staging system. Chest, 136, 260-271.
2. Arribalzaga, E.B. (2009) New tumor, node, metastasis staging system for lung cancer. J. Thorac. Oncol., 4, 1301; author reply 1301-1301; author reply 1302.
3. Visbal, A.L. et al. (2005) Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest, 128, 2933-2943.
4. Waller, D. et al. (2004) Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg., 26, 173-182.
5. Dômont, J. et al. (2005) Adjuvant chemotherapy in early-stage non-small cell lung cancer. Semin. Oncol., 32, 279-283.
6. Azzoli, C.G. (2005) Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer? Nat. Clin. Pract. Oncol., 2, 552-553.
7. Bhattacharjee, A. et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA, 98, 13790-13795.
8. Lacroix, L. et al. (2008) Gene expression profiling of non-small-cell lung cancer. Expert Rev. Mol. Diagn., 8, 167-178.
9. Garber, M.E. et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA, 98, 13784-13789.
10. Buyse, M. et al.; TRANSBIG Consortium. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst., 98, 1183-1192.
11. Slodkowska, E.A. et al. (2009) MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev. Mol. Diagn., 9, 417-422.
12. Chen, G. et al. (2011) Development and validation of a quantitative realtime polymerase chain reaction classifier for lung cancer prognosis. J. Thorac. Oncol., 6, 1481-1487.
13. Subramanian, J. et al. (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J. Natl. Cancer Inst., 102, 464-474.
14. Sartor, M.A. et al. (2010) ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics, 26, 456-463.
15. Cox, J. et al. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol., 26, 1367-1372.
16. Bendtsen, J.D. et al. (2004) Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel., 17, 349-356.
17. Möller, S. et al. (2001) Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics, 17, 646-653.
18. Bendtsen, J.D. et al. (2004) Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol., 340, 783-795.
19. Nakai, K. et al. (1999) PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem. Sci., 24, 34-36.
20. Chen, Y. et al. (2005) SPD-a web-based secreted protein database. Nucleic Acids Res., 33(Database issue), D169-D173.
21. Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507.
22. Hassan, K.A. et al. (2009) An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin. Cancer Res., 15, 6386-6390.
23. Shedden, K. et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med., 14, 822-827.
24. Irizarry, R.A. et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-264.
25. Bild, A.H. et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439, 353-357.
26. Okayama, H. et al. (2012) Identification of genes upregulated in ALKpositive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res., 72, 100-111.
27. Raponi, M. et al. (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res., 66, 7466-7472.
28. Ishwaran, H. et al. (2007) Random survival forests for R. R News 7, 7.
29. Ishwaran, H. et al. (2008) Random survival forests. Ann. Appl. Statist., 2, 20.
30. McShane, L.M. et al.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. (2005) Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol., 23, 9067-9072.
31. Alonzo, T.A. (2005) Standards for reporting prognostic tumor marker studies. J. Clin. Oncol., 23, 9053-9054.
32. Omenn, G.S. et al. (2012) Evolution of Translational Omics: Lessons Learned and the Path Forward. Institute of Medicine of National Academies Press, Washington, DC.
33. Hayes, D.F. et al. (2013) Breaking a vicious cycle. Sci. Transl. Med., 5, 196cm6.
34. Keshamouni, V.G. et al. (2009) Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J. Proteome Res., 8, 35-47.
35. Keshamouni, V.G. et al. (2006) Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J. Proteome Res., 5, 1143-1154.
36. Ramaswamy, S. et al. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet., 33, 49-54.
37. Felip, E. et al.; ESMO Guidelines Task Force. (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of nonsmall-cell lung cancer (NSCLC). Ann. Oncol., 16 (suppl. 1), i28-i29.
38. Scagliotti, G.V. et al.; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J. Natl. Cancer Inst., 95, 1453-1461.
39. Johnson, B.E. et al. (2005) Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin. Cancer Res., 11(13 Pt 2), 5022s-5026s.
40. Keller, S.M. et al. (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med., 343, 1217-1222.
41. Douillard, J.Y. et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol., 7, 719-727.
42. Arriagada, R. et al.; International Adjuvant Lung Cancer Trial Collaborative Group. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med., 350, 351-360.
43. Jang, R.W. et al. (2009) Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J. Clin. Oncol., 27, 4268-4273.
44. Arriagada, R. et al. (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol., 28, 35-42.
45. Paik, S. (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist, 12, 631-635.
46. Faivre, S. et al. (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol., 33, 407-420.
47. Sun, S. et al. (2007) New molecularly targeted therapies for lung cancer. J. Clin. Invest., 117, 2740-2750.
48. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
49. Reka, A.K. et al. (2010) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol. Cancer Ther., 9, 3221-3232.
50. Reka, A.K. et al. (2011) Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J. Thorac. Oncol., 6, 1784-1792.